1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AnnJi

AnnJi

7754.TWO
AnnJiTW flagTaipei Exchange
63.20
TWD
-1.60
- -
6.37BMarket Cap
AnnJi
7754.TWO
(Taipei Exchange)

Recent

price

63.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
FRC
0.02
0.02
1.52
1.02
- -
Revenue per Share
-2.11
-3.58
-3.49
-3.75
- -
Basic EPS, GAAP
-1.53
-2.9
-0.84
-2.08
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
2.58
0.63
-0.4
-3.83
- -
Book Value per Share
4.74
5.17
8.38
5.95
- -
Tangible Book Value per Share
94
66
94
94
- -
Basic Weighted Avg Shares
1
2
144
96
8
Sales/Revenue/Turnover
-14,095.82
-14,790.59
-187.15
-373.4
-4,891.01
Operating Margin (%)
42
40
38
45
45
Depreciation Expense
-199
-237
-329
-354
-358
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-13,841.46
-14,554.12
-229.37
-367.02
-4,738.73
Profit Margin (%)
396
275
691
453
267
Working Capital
- -
- -
55
49
43
LT Debt
650
511
925
662
320
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-165.74
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-51.7%
Free Cash Flow
- -
- -
80.14%
Net Income, GAAP
- -
- -
1.1%
Sales/Revenue/Turnover
- -
- -
-92.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
144
2024
- -
- -
- -
- -
96
2025
- -
- -
- -
- -
8

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-3.49
2024
- -
- -
- -
- -
-3.75
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
Gilead Sciences, Inc. (GILD.SW)
Savior Lifetec Corp. (4167.TWO)
IntelGenx Technologies Corp. (IGX.TO)
Dyadic International, Inc. (DYAI)
Adaptimmune Therapeutics plc (ADAPY)
Business
AnnJi Pharmaceutical Co., Ltd. (7754.TWO) operates as a clinical-stage biopharmaceutical company focused on developing first-in-class small molecule new chemical entities (NCEs) targeting neurology, dermatology, and inflammatory disorders; its pipeline includes AJ201, a nuclear factor E2-related factor 2 (Nrf2) activator oral suspension for treating neurodegenerative diseases such as spinal and bulbar muscular atrophy (SBMA); AJ302, a highly selective histone deacetylase 6 (HDAC6) inhibitor sustained-release injection for preventing and treating chemotherapy-induced peripheral neuropathy (CIPN); AJ202, a next-generation scalp topical androgen degradation promoter for male pattern baldness (androgenetic alopecia); AJ303, an anti-fibrotic and anti-inflammatory compound for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases; and AJ101, a topical cream androgen receptor degradation enhancer with anti-inflammatory and antioxidant properties for acne vulgaris. Founded in 2014 and headquartered at 16F.-6, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan, the company directs its innovative drug projects primarily toward high-unmet-need indications, including orphan drugs, with products targeted at European and American markets. In recent developments, AnnJi listed its shares on the Taipei Exchange (TPEX) in June 2024; licensed intellectual property rights for AJ201 to partner Avenue Therapeutics in February 2023, though Avenue received a notice of intent to terminate from AnnJi in March 2025; and advanced its pipeline with Phase 1 clinical trials for AJ302 expected around 2021 alongside ongoing preclinical and early clinical efforts for other candidates amid 2025Q2 financial reporting.